300 related articles for article (PubMed ID: 15481440)
21. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
22. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
24. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Vartholomatos G
Cell Mol Life Sci; 2018 Jun; 75(11):1999-2009. PubMed ID: 29484447
[TBL] [Abstract][Full Text] [Related]
25. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
26. Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.
Kalinkova L; Sevcikova A; Stevurkova V; Fridrichova I; Ciernikova S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614080
[TBL] [Abstract][Full Text] [Related]
27. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
29. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
30. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
31. Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Stresemann C; Bokelmann I; Mahlknecht U; Lyko F
Mol Cancer Ther; 2008 Sep; 7(9):2998-3005. PubMed ID: 18790780
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
33. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic deregulation in myeloid malignancies.
Meldi KM; Figueroa ME
Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation in haematological malignancies: the role of decitabine.
Hennessy BT; Garcia-Manero G; Kantarjian HM; Giles FJ
Expert Opin Investig Drugs; 2003 Dec; 12(12):1985-93. PubMed ID: 14640942
[TBL] [Abstract][Full Text] [Related]
36. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Figueroa ME; Skrabanek L; Li Y; Jiemjit A; Fandy TE; Paietta E; Fernandez H; Tallman MS; Greally JM; Carraway H; Licht JD; Gore SD; Melnick A
Blood; 2009 Oct; 114(16):3448-58. PubMed ID: 19652201
[TBL] [Abstract][Full Text] [Related]
37. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg.
Esteller M
Clin Immunol; 2003 Oct; 109(1):80-8. PubMed ID: 14585279
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
Craddock C
Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
[No Abstract] [Full Text] [Related]
39. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Abáigar M; Ramos F; Benito R; Díez-Campelo M; Sánchez-del-Real J; Hermosín L; Rodríguez JN; Aguilar C; Recio I; Alonso JM; de las Heras N; Megido M; Fuertes M; del Cañizo MC; Hernández-Rivas JM
Ann Hematol; 2013 Nov; 92(11):1543-52. PubMed ID: 23740492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
